Biotechnology today is no longer driven by discovery alone.
It is driven by precision, reproducibility and the ability to translate science into scalable impact.
From biosimilar drug development to diagnostics, immunology, and cell-based research, the life sciences ecosystem is under pressure to deliver results that are not only innovative but reliable, affordable and globally relevant.
This is where deNOVO Biolabs has quietly emerged as a critical enabler.
Founded with the vision of strengthening India’s biotech self-reliance while meeting global quality expectations, deNOVO Biolabs has grown into a trusted partner for biosimilar developers, biopharma companies, CROs and academic researchers worldwide .
Vision to Vanguard: Our Journey
deNOVO Biolabs was founded in 2013 by a group of next-generation technocrats inspired by national innovation initiatives such as BIRAC and the Karnataka Vision Group .
What began as a mission to strengthen India’s biotech manufacturing ecosystem soon led to several industry-first milestones:
- India’s first manufacturer of PK & Immunogenicity ELISA kits for biosimilar programs
- Trusted partner to 6 of the top 10 Indian biosimilar companies
- A growing international footprint built on quality, speed, and affordability
- Operations headquartered in Bangalore Biotech Park, India’s life sciences hub
This evolution reflects a deeper philosophy:
Build locally. Perform globally. Deliver reliably.
Our Leadership
deNOVO’s leadership team combines deep scientific expertise with operational discipline, enabling the company to support projects from early discovery through commercialization.
Led by co-founders Dr. Dinesh Kumar Saini, Dr. Manjunath S. Devaramani, and Mr. Babulal Saini, along with a strong technical and commercial leadership bench, deNOVO operates with a clear focus on:
- Scientific rigour
- Regulatory readiness
- Customer-centric problem solving
- Long-term partnerships rather than transactional supply
This approach is reinforced by a Scientific Advisory Board and strong academic–industry collaborations, ensuring that solutions remain both relevant and future-ready .
What makes deNOVO so unique?
Several factors differentiate deNOVO from both global suppliers and local competitors:
1. Indigenous Manufacturing
deNOVO is the first Indian company to manufacture molecular biology research products entirely in-house, enabling tight quality control and faster innovation cycles .
2. Faster Turnaround Times
Local manufacturing eliminates long import timelines, allowing research programs to move faster—an increasingly critical advantage in competitive drug development environments.
3. End-to-End Supply Chain Control
From raw materials to final delivery, deNOVO manages the entire supply chain for most products, reducing variability and supply risk.
4. Dedicated Local Technical Support
Unlike many imported brands, deNOVO offers local, hands-on technical support, helping teams troubleshoot assays and workflows quickly.
5. Global Quality
High-quality reagents, kits, and servicesdelivered at competitive pricing, enable broader access without compromising performance.
6. Certified Quality Systems
deNOVO operates under ISO 9001:2015, ISO 13485:2016, CPCSEA, and IBSC compliance frameworks, reinforcing regulatory confidence .
Our Product Portfolio
deNOVO’s offerings are designed to support precision-driven life sciences, particularly in biosimilars, diagnostics, and immunology.
PK & Immunogenicity ELISA Kits
Gold-standard ELISA kits developed specifically for biosimilar pharmacokinetics and anti-drug antibody (ADA) studies, delivering high sensitivity and reproducibility.
Cytokine & Small Molecule ELISA Kits
Robust biomarker quantification tools for:
- Immunology
- Inflammation research
- Therapeutic monitoring
Recombinant Proteins & Antibodies
High-purity, customizable proteins and antibodies optimized for:
- ELISA
- Western blotting
- Flow cytometry
- Functional assays
Assay Reagents & Media
A complete suite including:
- Cell culture media
- Normal serum
- Purified IgG
- Buffers and specialty reagents
These inputs form the backbone of reproducible, lifecycle-ready assays.
Our Research Services
Recognizing that tools alone are not enough, deNOVO provides customized research services that address real-world bottlenecks.
Custom Antibody Development
- mAb development in Balb/c mice
- pAb development in rabbit, goat, guinea pig
- Scale-up, purification, and characterization
- ELISA pair selection
Biosimilar-Specific Services
- SPR binding studies
- Antibody labeling (HRP, Biotin)
- PK & ADA method development
Cell-Based Assays
In vitro cellular models that mimic clinical scenarios for drug discovery and validation.
Gene & Protein Synthesis
- Gene, probe, and primer synthesis
- Cloning and subcloning
- Protein expression and purification in E. coli
Lateral Flow Assay (LFA) Development
Custom point-of-care diagnostic solutions for infectious diseases and emergency healthcare.
These services allow clients to bridge analytical gaps, reduce risk, and accelerate decision-making.
Our Collaborations
deNOVO’s credibility is reflected in its collaborations with:
- Leading biosimilar manufacturers
- Global biopharma companies
- Premier academic institutions
- CROs and diagnostic innovators
Clients include organizations such as Lupin, Zydus, Intas, Sun Pharma, Syngene, Reliance Life Sciences, Gennova, Ghent University, and many more .
This ecosystem approach enables faster translation of science into real-world healthcare solutions.
Partner with deNOVO Biolabs
If your team is working on:
- Biosimilars
- Immunology
- Diagnostics
- Cell-based assays
- PK/ADA studies
- Custom assay development
deNOVO Biolabs is ready to support your next breakthrough.
📩 Contact: info@denovobiolabs.com
🌐 Website: www.denovobiolabs.com
Email to register for our next webinar on 20 December, 2025 at 11 am IST
Let’s discover, innovate and collaborate – together.